developing

IFQM Symposium 2025 Concludes with a Call for Quality & Innovation to Make India Globally Competitive

India is at the cusp of developing and making products for the world, with quality that is of international standards,…

1 day ago

EyePoint Announces Proposed Public Offering of Common Stock

October 14, 2025 16:35 ET  | Source: EyePoint Pharmaceuticals, Inc. WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals,…

1 day ago

OXCCU Raises $28m in Series B Funding to Scale Sustainable Aviation Fuel from Waste Carbon

Backed by global leaders in aviation, energy, and climate investing, OXCCU strengthens its position as a critical player in the global…

2 weeks ago

LifeSpan Portfolio Company Remedium Signs Landmark Deal with Eli Lilly

NORWALK, Conn., Sept. 23, 2025 /PRNewswire/ -- Lifespan Vision Ventures is pleased to announce that its portfolio company, Remedium Bio,…

3 weeks ago

STARLight Project chosen as the European consortium to take the lead in next-generation Silicon Photonics on 300mm wafers

STARLight Project chosen as the European consortium to take the lead in next-generation Silicon Photonics on 300mm wafers 24 leading…

3 weeks ago

GameChange Solar Featured in The Wall Street Journal on Saudi Arabia’s Solar Expansion

NORWALK, Conn., Sept. 22, 2025 /PRNewswire/ -- The Wall Street Journal recently featured GameChange Solar in an article on Saudi Arabia's…

3 weeks ago

Revive Therapeutics Announces Closing of Second Tranche of Private Placement

TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a…

4 weeks ago

Altair and Gordon Murray Group Developing Groundbreaking Ultra Lightweight Platform

Collaboration leverages advanced simulation technology to drive innovation in next-generation vehicle design TROY, Mich., Sept. 18, 2025 /PRNewswire/ -- Altair, a…

4 weeks ago

Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum

September 12, 2025 07:00 ET  | Source: Cullinan Therapeutics, Inc. CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics,…

1 month ago

NanoNewron Awarded $2.5 Million in NIH STTR Phase 2 Grant to Advance its Innovative NN-840 Alzheimers Disease Program

The $2.5 Million in NIH STTR Phase 2 Grant allows NanoNewron to start the IND-enabling program for the NN-840 program…

1 month ago